Full Press Release Details
Poster Presentations Highlight Baseline Characteristics from the Phase 3 VANQUISH-2 Trial of Subcutaneous VK2735 and the Impact of VK2735 on Obesity Severity and Cardiometabolic Parameters in the Phase 2 VENTURE Study
SAN DIEGO, Nov. 9, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it will present two posters highlighting its VK2735 program at The Obesity Society's Annual Meeting, ObesityWeek®, taking place from November 14–17, 2026, in Washington, D.C. VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors that Viking is developing in subcutaneous and oral formulations for the potential treatment of various metabolic disorders, including obesity.
Details of the ObesityWeek poster presentations are as follows:
Title: VANQUISH-2 SC VK2735 Study in Adults With Overweight and Type 2 Diabetes: Baseline Characteristics
Presented by: Jamy Ard, MD, FTOS
Track: Diabetes, Weight Management & Sex Specific Outcomes
Date/Time: Saturday, November 14, 2026, 7:30 pm to 8:30 pm ET (Poster Session 1)
Location: Exhibit Hall BCD, Gaylord National Resort & Convention Center
Title: Impact of SC VK2735 on Obesity Severity and Cardiometabolic Parameters in the VENTURE Study
Presenter: Harold Bays, MD, MFOMA, FTOS, FACC, FNLA, FASPC, DABOM
Track: Clinical Trials: Efficacy, Safety & Weight Loss Outcomes
Date/Time: Sunday, November 15, 2026, 2:30 pm to 3:30 pm ET (Poster Session 2)
Location: Exhibit Hall BCD, Gaylord National Resort & Convention Center
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company advancing a next-generation portfolio of therapies for obesity and metabolic disease. Guided by deep expertise in metabolic biology and rigorous science, Viking is developing innovative treatments to help people achieve meaningful, lasting health improvements by treating obesity first. The company's lead program, VK2735, is a dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist in development in both subcutaneous and oral formulations for obesity. VK2735 is currently being evaluated in Phase 3 clinical studies for obesity, along with maintenance dosing strategies designed to support long-term weight management. Viking is also advancing additional obesity programs, including VK3019, an amylin receptor agonist, VK2809, an orally available thyroid hormone receptor beta agonist for metabolic and liver disease, and VK0214 for the rare genetic disorder X-linked adrenoleukodystrophy (X-ALD).
For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding Viking Therapeutics, Inc., under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Viking's expectations regarding its clinical and preclinical development programs, anticipated timing for reporting clinical data and cash resources. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of Viking's product candidate development activities and clinical trials, including those for VK2735, VK3019, VK0214, VK2809, and the company's other incretin and other receptor agonists; risks that prior clinical and preclinical results may not be replicated; risks regarding regulatory requirements; and other risks that are described in Viking's most recent periodic reports filed with the Securities and Exchange Commission including Viking's Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent Quarterly Reports on Form 10-Q, including the risk factors set forth in those filings. These forward-looking statements speak only as of the date hereof. Viking disclaims any obligation to update these forward-looking statements except as required by law.